The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Incidence of and Risk Factors for Colistin-Associated Nephrotoxicity in a Large Academic Health System
Open accessAbstract
Background.Colistin, originally abandoned due to high rates of nephrotoxicity, has been recently reintroduced due to activity against carbapenem-resistant Gram-negative organisms.Recent literature, largely obtained from outside the United States, suggests a lower rate of nephrotoxicity than historically reported. Methods.A retrospective cohort of all patients who received colistin for $48 hours at the Detroit Medical Center over a 5-year period was performed to determine the rate of colistin-associated nephrotoxicity as defined by the RIFLE criteria.Results.Fifty-four (43%) patients in the cohort developed nephrotoxicity.Patients who experienced nephrotoxicity after colistin administration were in the Risk (13%), Injury (17%), or Failure (13%) categories per RIFLE criteria.Patients who developed nephrotoxicity received significantly higher mean doses than those who did not (5.48 mg/kg per day vs 3.95 mg/kg per day; P , .001), and the toxicity occurred in a dose-dependent fashion.Independent predictors for nephrotoxicity were a colistin dose of $5.0 mg/kg per day of ideal body weight (odds ratio [OR], 23.41; 95% confidence interval [CI], 5.3-103.55),receipt of concomitant rifampin (OR, 3.81; 95% CI, 1.42-10.2),and coadministration of $3 concomitant nephrotoxins (OR, 6.80; 95% CI, 1.42-32.49). Conclusions.In this retrospective cohort, nephrotoxicity (as defined by RIFLE criteria) occurred among 43% of treated patients in a dose-dependent manner.Higher colistin doses, similar to those commonly used in the United States, led to a relatively high rate of nephrotoxicity.These data raise important questions regarding the safe use of colistin in the treatment of multidrug-resistant pathogens.Colistin, a polymyxin antimicrobial agent, was originally used in the 1960s, but due to nephrotoxicity rates approaching 50%, it was abandoned as other ''less toxic'' antimicrobials became available [1].Colistin has recently reemerged as a last line therapeutic agent for the treatment of multidrug-resistant pathogens including Acinetobacter baumannii, Pseudomonas aeruginosa, and carbapenem-resistant Enterobacteriaceae.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Falagas, M. E., & Kasiakou, S. K. (2006) · Critical Care · doi:10.1186/cc3995 · Cited by 828
Garonzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Lodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-07 · Cited by 574
Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., Karaiskos, I., Poulakou, G., Kontopidou, F., Armaganidis, A., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01361-08 · Cited by 494
Jeffres, M. N., Isakow, W., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.014 · Cited by 334
Falagas, M. E., Rafailidis, P. I., Ioannidou, E., Alexiou, V. G., Matthaiou, D. K., Karageorgopoulos, D. E., Kapaskelis, A., Nikita, D., & Michalopoulos, A. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.005 · Cited by 300
Michalopoulos, A. S., Tsiodras, S., Rellos, K., Mentzelopoulos, S., & Falagas, M. E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.01043.x · Cited by 292
Markou, N., Apostolakos, H., Koumoudiou, C., Athanasiou, M., Koutsoukou, A., Alamanos, I., & Gregorakos, L. (2003) · Critical Care · doi:10.1186/cc2358 · Cited by 278
Toxicity after prolonged (more than four weeks) administration of intravenous colistin
Falagas, M. E., Rizos, M., Bliziotis, I. A., Rellos, K., Kasiakou, S. K., & Michalopoulos, A. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-1 · Cited by 242
Markou, N., Markantonis, S. L., Dimitrakis, E., Panidis, D., Boutzouka, E., Karatzas, S., Rafailidis, P., Apostolakos, H., & Baltopoulos, G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.01.015 · Cited by 191
Colistin Dosing and Nephrotoxicity in a Large Community Teaching Hospital
DeRyke, C. A., Crawford, A. J., Uddin, N., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01707-09 · Cited by 178
Definition and Classification of Acute Kidney Injury
Kellum, J. A., Bellomo, R., & Ronco, C. (2008) · Nephron Clinical Practice · doi:10.1159/000142926 · Cited by 174
Ingram, P. R., Lye, D. C., Tambyah, P. A., Goh, W. P., Tam, V. H., & Fisher, D. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn080 · Cited by 163
Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features
De Vriese, A., Robbrecht, D., Vanholder, R., Vogelaers, D., & Lameire, N. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9428460 · Cited by 135
Acute renal failure due to rifampicin: A study of 25 patients
Muthukumar, T., Matcha, J., Fernando, E. M., & Muthusethupathi, M. A. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.35675 · Cited by 117
Polymyxins (Polymyxin B and Colistin)
Kaye, K. S., Pogue, J. M., & Kaye, D. (2015) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-1-4557-4801-3.00031-x · Cited by 19
Self-citationRifampicin-associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis
Wiggins, K. J., Galanos, J., Hill, P., Scott, K. V., & Langham, R. G. (2007) · Journal of Nephrology · doi:10.1093/joneph/20.4.489 · Cited by 7
Cited by
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Giacobbe, D. R., Viscoli, C., Giamarellou, H., Karaiskos, I., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2209 · Cited by 949
Self-citationTamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1013 · Cited by 519
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv050 · Cited by 435
Self-citationDurante-Mangoni, E., Signoriello, G., Andini, R., Mattei, A., De Cristoforo, M., Murino, P., Bassetti, M., Malacarne, P., Petrosillo, N., Galdieri, N., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit253 · Cited by 405
Metadata
- Authors
- Pogue, J. M., Lee, J., Marchaim, D., Yee, V., Zhao, J. J., Chopra, T., Lephart, P., & Kaye, K. S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09-07
- Volume
- 53
- Issue
- 9
- Pages
- 879-884
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2162268639
- Cited by
- 327
- References
- 18
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.